Ligand Binding Assays (LBA) Archives - AIT BioscienceAIT Bioscience


Tag Archives for Ligand Binding Assays (LBA)

AIT Bioscience Announces New High-Resolution Mass Spectrometry Service Line

Synergistic Addition to Protein, Peptide, Antibody,   and ADC Offerings     At AIT Bioscience, we recently expanded our service offerings to include high-resolution mass spectrometry (HRMS).The Thermo Q-Exactive Plus® platform allows us to offer new capabilities in mass spectrometry including assays for conjugated peptides, fusion proteins, antibodies, and antibody drug conjugates (ADC’s). These HRMS … read the full article » »

Categories: High-Resolution Mass Spectrometry (HRMS), LC-MS/MS Methods, Ligand Binding Assays (LBA)

Other Tags: , , , , , , ,

Comments Off on AIT Bioscience Announces New High-Resolution Mass Spectrometry Service Line


AIT Bioscience Acquires New Instrumentation

New Mass Spectrometer Expands Lab Capacity     AIT Bioscience recently invested in a new Q Exactive™ Hybrid Quadrupole-Orbitrap™ Mass Spectrometer. This new instrument will allow AIT Bioscience to enhance its discovery protein mass spec capabilities and create additional capacity for protein and peptide work. This equipment will also improve method sensitivity and provide added … read the full article » »

Categories: LC-MS/MS Methods, Ligand Binding Assays (LBA)

Other Tags: , , , ,

Comments Off on AIT Bioscience Acquires New Instrumentation


AIT Bioscience Positions for Growth

AIT Bioscience Positions for Growth AIT Bioscience recently added to its leadership team   and is excited to introduce Mark Cameron, Vice President,   Scientific Services, Ligand Binding Assays (LBA).         Mark Cameron joins AIT Bioscience as the Vice President, Scientific Services, Ligand Binding Assays (LBA). Mark brings more than 25 years … read the full article » »

Categories: Ligand Binding Assays (LBA), News

Other Tags:

Comments Off on AIT Bioscience Positions for Growth


Biosimilar Drug Development-Establishing PK and Immunogenicity Equivalence

Biosimilar Drug Development07:29:59 How We (and the FDA) Establish PK and Immunogenicity Bioequivalence One key question AIT Bioscience regularly receives is: “Is it better to use two separate PK or immunogenicity assays to analyze the reference product and the biosimilar, or should we use a one-assay approach?” Our advice has always been in the interest … read the full article » »

Categories: ELISA, Immunoassay, Ligand Binding Assays (LBA), Uncategorized

Other Tags:

Comments Off on Biosimilar Drug Development-Establishing PK and Immunogenicity Equivalence